ESR1 and breast cancer: Introduction of a kinase-dead (KD) GSK3B construct into estrogen receptor positive MCF-7 breast cancer cells increased their resistance to the chemotherapeutic drug doxorubicin and the estrogen receptor antagonist 4-hydroxytamoxifen (4HT) [80].